Drug Trial Radar · NCT00613457
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
Last checked: Nov 19, 2026Latest source record: Jan 14, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,039
Actual
Start
Sep 2000
Primary completion
Jul 2006
Study completion Jul 2006
Sponsor
- Lead sponsor
- Associazione Italiana Ematologia Oncologia PediatricaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 13, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 year, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating young patients with acute lymphoblastic leukemia. PURPOSE: Thisphase III trial is studying several different combination chemotherapy regimens to compare how well they work in treating young patients with acute lymphoblastic leukemia.
Conditions
- Leukemia
Interventions
dexamethasoneDrug
10 mg/sqm/day from for 21 days
asparaginaseDrug
native E-coli Asparaginase 5,000 IU/sqm x 8 doses
AsparaginaseDrug
native E-Coli Asparaginase 10,000 IU/sqm x 4 doses
cyclophosphamideDrug
1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III
cytarabineDrug
75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III
daunorubicinDrug
30 mg/sqm i.v. 4 doses in Induction phase
doxorubicinDrug
30 mg/sqm i.v. x 4 doses in Protocol II and III
EtoposideDrug
100 mg/sqm i.v. for 3 doses in HR block 3
IfosfamideDrug
800 mg/sqm i.v.q12h x 5 in HR block 2
mercaptopurineDrug
60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase
MethotrexateDrug
by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance
prednisoneDrug
60 mg/sqm daily p.o. for 28 days then tapered in Induction phase
thioguanineDrug
60 mg/sqm p.o. x 14 days in Protocol II and Protocol III
VincristineDrug
1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1
VindesineDrug
3 mg/sqm i.v. x 2 doses in HR block 2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of dexamethasone vs prednisone during the induction phaseTime frame: 5 years
- Event-free survival (EFS) and overall survival after initial remission in intermediate-risk and high-risk patientsTime frame: 5 years
- Safety and efficacy of treatment reduction during reintensification in standard-risk patientsTime frame: 5 years
- EFS after second delayed reintensification in intermediate-risk patientsTime frame: 5 years
- Outcome after extended reintensification therapy in high-risk patientsTime frame: 5 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.